Cleave Biosciences' Series B Round

Cleave Biosciences raised a round of funding on August 08, 2016.

Cleave Biosciences develops drugs that target protein homeostasis systems and improve the treatment of solid tumors and hematologic malignancies. The company's CB-5083 is an oral inhibitor of p97, a c…

Articles about Cleave Biosciences' Series B Round: